Merck and Eisai Receive Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Plus LENVIMA® (Lenvatinib) in Two Different Types of Cancer

Merck announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted positive opinions recommending approval of the combination of KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, for two different indications.
[Merck (BusinessWire, Inc.)]
[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Immune-Onc Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating IO-108, a Novel Antagonist Antibody Targeting LILRB2 (ILT4), in Patients with Advanced Solid Tumors

Immune-Onc Therapeutics, Inc. announced that the first patient has been dosed in the company’s first-in-human clinical trial of IO-108, a novel antagonist antibody targeting the myeloid checkpoint Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) for the treatment of solid tumors.
[Immune-Onc Therapeutics, Inc.]
[zotpress userid=’7992332′ items=’CCCCCCCC’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Prognostic Implications of Tumor-Infiltrating T Cells in Early-Stage Endometrial Cancer

The proportion of T cells and their subpopulations were associated with clinicopathological features and relapse-free survival outcomes. CD3+ CD4+ infiltrates were more abundant in the patients with higher grade or non-endometrioid histology.
[Modern Pathology]
[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Single-Cell Profiling Reveals the Importance of CXCL13/CXCR5 Axis Biology in Lymphocyte-Rich Classic Hodgkin Lymphoma

Researchers examined the immune cell profile of eight cell suspension samples of Lymphocyte-rich classic Hodgkin lymphoma (LR-CHL) in comparison to 20 samples of the mixed cellularity and nodular sclerosis subtypes of CHL.
[Proceedings of the National Academy of Sciences of the United States of America]
[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Leukemic Progenitor Cells Enable Immunosuppression and Post-Chemotherapy Relapse via IL-36–Inflammatory Monocyte Axis

Researchers showed that abnormal IL-36 production activated by NF-κB was an essential feature of mouse and human leukemic progenitor cells.
[Science Advances]
[zotpress userid=’7992332′ items=’BBBBBBBB’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Heterogeneous Distribution of PD-L1 Expression in the IASLC/ATS/ERS Classification of Lung Adenocarcinoma

94 lung adenocarcinoma cases were reviewed in the Third Affiliated Hospital of Soochow University from January to December 2019. PD-L1 (DAKO 22C3) was used to test the PD-L1 expression in lung cancer tissue.
[International Journal of Clinical Oncology]
[zotpress userid=” items=’45XWATNZ’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Surface Oncology Announces New Randomized Phase II Clinical Study Evaluating SRF388 in Patients with First-Line Hepatocellular Carcinoma in Clinical Collaboration with Roche

Surface Oncology, an immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced details about its plan to initiate a randomized Phase II clinical study evaluating SRF388, in combination with Roche’s atezolizumab and bevacizumab, in patients with treatment-naïve hepatocellular carcinoma.
[Surface Oncology]
[zotpress userid=’7992332′ items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Antigen Presentation by Lung Epithelial Cells Directs CD4+TRM Cell Function and Regulates Barrier Immunity

Researchers reported that lung epithelial cells, including distinct surfactant protein C (SPC)lowMHChigh epithelial cells, functioned as anatomically-segregated and temporally-dynamic antigen presenting cells.
[Nature Communications]
[zotpress userid=” items=’45XWATNZ’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

BET Protein Degradation Triggers DR5-Mediated Immunogenic Cell Death to Suppress Colorectal Cancer and Potentiate Immune Checkpoint Blockade

Researchers found that inducing the degradation of bromodomain and extra-terminal domain (BET) proteins by the proteolysis targeting chimeras approach potently suppressed the growth of colorectal cancer including patient-derived tumors.
[Oncogene]
[zotpress userid=’7992332′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Therapeutic Effectiveness and Safety of Sintilimab-Dominated Triple Therapy in Unresectable Hepatocellular Carcinoma

Scientists evaluated the effectiveness and safety of sintilimab, a programmed cell death protein-1 blockade, combined with sorafenib and transhepatic arterial chemotherapy and embolization in patients with unresectable hepatocellular carcinoma, compared with sintilimab monotherapy and sintilimab-sorafenib duotherapy.
[Scientific Reports]
[zotpress userid=’7992332′ items=’CCCCCCCC’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Atovaquone-HSA Nano-Drugs Enhance the Efficacy of PD-1 Blockade Immunotherapy by Alleviating Hypoxic Tumor Microenvironment

The authors exploited atovaquone/albumin nanoparticles to improve bioavailability and tumor targeting of atovaquone, enhancing the efficacy of anti-PD-1 therapy by normalizing tumor hypoxia.
[Journal of Nanobiotechnology]
[zotpress userid=’7992332′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full ArticleGraphical Abstract
Bookmark

No account yet? Register

Share
Share